Investigating how GLUT1 contributes to heart problems in diabetes
Official title: Role of GLUT1 in diabetic cardiomyopathy
Funded at University of Cincinnati · NIH-11127844 · Data updated 2026-11-12
This study is looking at how a protein called GLUT1 affects heart health in people with diabetes, especially when diabetes causes heart problems, and it hopes to find new ways to help treat these heart issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project start | May 1, 2025 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $749,360 |
| NIH project number | 1R01HL175251-01A1 |
| Project ID | NIH-11127844 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with Type-1 or Type-2 diabetes who are experiencing heart problems.
✕Less likely to help
Patients without diabetes or those whose heart issues are caused by other conditions unrelated to diabetes may not benefit from this research.
What this research studies
This research focuses on understanding the role of the GLUT1 glucose transporter in diabetic cardiomyopathy, a condition where diabetes leads to heart failure without other heart diseases. The study will explore how GLUT1 affects heart cells and contributes to heart damage through mechanisms involving oxidative stress and fat toxicity. By examining both human heart samples and mouse models, the researchers aim to uncover the signaling pathways that GLUT1 activates and how inhibiting GLUT1 might offer new treatment options for patients with diabetes-related heart issues.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that prevent or treat heart failure in diabetic patients.
How similar studies have gone: Previous research has shown promising results in targeting glucose transporters for heart disease treatment, suggesting that this approach could be beneficial.
Where this research is happening
-
University of Cincinnati
Cincinnati, United States Active
Researchers
- Principal investigator: Drosatos, Konstantinos — University of Cincinnati
- Study coordinator: Drosatos, Konstantinos
Related research
Other NIH-funded projects on the same topics.
-
Global bromocriptine trial for postpartum cardiomyopathy
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with peripartum cardiomyopathy.
-
Global Bromocriptine Add-on for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding the dopamine agonist bromocriptine to standard heart failure care helps postpartum women with a specific heart condition.
-
Global Bromocriptine Trial for Postpartum Heart Failure (GLOBal PPCM)
A large international study will test whether adding bromocriptine to standard heart-failure care helps women with postpartum cardiomyopathy.
-
Bromocriptine as add-on therapy for postpartum cardiomyopathy across multiple sites
A large international study will test whether adding bromocriptine to standard heart failure treatment helps new mothers with postpartum cardiomyopathy.
-
Global bromocriptine trial to help postpartum heart failure patients
A large international trial tests whether adding bromocriptine to standard heart failure treatment improves outcomes for new mothers with a specific pregnancy-related heart condition.
-
Global Bromocriptine Trial to Help Postpartum Heart Failure
A large international study will test whether adding bromocriptine to standard heart failure treatment helps women with postpartum cardiomyopathy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.